Alpha 2.0
Login Register
» Authors » Gandham Mahendra

Gandham Mahendra

Explore the profile of Gandham Mahendra including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 111
Followers 0
Related Specialties
Pharmacology
Genetics
Oncology
Top 10 Co-Authors
Sanjay Kumar
Selvarangan Ponnazhagan
William E Grizzle
Denise R Shaw
Sreelatha Meleth
Pierre L Triozzi
Tatyana Isayeva
David T Curiel
Arie Sitthichai Mobley
Mary T Lucero
Published In
Hum Gene Ther
J Virol
Cancer Gene Ther
Cancer Res
Biochim Biophys Acta
Affiliations
Soon will be listed here.
Recent Articles
1.
Evidence for multiple signaling pathways in single squid olfactory receptor neurons
Mobley A, Mahendra G, Lucero M
J Comp Neurol . 2007 Jan; 501(2):231-42. PMID: 17226749
At least two different G-protein-mediated transduction cascades, the adenylate cyclase and phospholipase C (PLC) pathway, process chemosensory stimuli for various species. In squid olfactory receptor neurons (ORNs), physiological studies indicate...
2.
Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction
Kumar S, Mahendra G, Ponnazhagan S
Biochim Biophys Acta . 2005 Oct; 1731(2):95-103. PMID: 16225939
Towards utilizing gene-targeted, repopulating mesenchymal stem cells (MSC) to increase osteogenesis, we evaluated the expression of bone-specific promoters during MSC differentiation. Multi-lineage potential of cultured MSC was confirmed by osteogenic,...
3.
Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy
Kumar S, Mahendra G, Nagy T, Ponnazhagan S
Hum Gene Ther . 2005 Feb; 15(12):1197-206. PMID: 15684696
Gene therapy for osteopenic conditions including osteoporosis is a potential alternative to pharmacotherapy for cost effectiveness, long-term viability, and the ability to enhance bone mass by anabolic approaches. Increased understanding...
4.
Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor
Mahendra G, Kumar S, Isayeva T, Mahasreshti P, Curiel D, Stockardt C, et al.
Cancer Gene Ther . 2004 Sep; 12(1):26-34. PMID: 15359287
Antiangiogenic gene transfer has the potential to be more efficacious than protein-based therapies or pharmacotherapies for the control of solid tumor growth, invasion and metastasis. For a sustained antiangiogenic effect,...
5.
Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant
Ponnazhagan S, Mahendra G, Lima J, Aldrich W, Jenkins C, Ren C, et al.
Hum Gene Ther . 2004 Sep; 15(9):856-64. PMID: 15353040
Recombinant adeno-associated virus 2 (rAAV) vectors have been successfully used for sustained expression of therapeutic genes. The potential of using rAAV as a cancer vaccine vector and the impact of...
6.
Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor
Ponnazhagan S, Mahendra G, Kumar S, Shaw D, Stockard C, Grizzle W, et al.
Cancer Res . 2004 Mar; 64(5):1781-7. PMID: 14996740
Angiogenesis is characteristic of solid tumor growth and a surrogate marker for metastasis in many human cancers. Inhibition of tumor angiogenesis using antiangiogenic drugs and gene transfer approaches has suggested...
7.
Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands
Ponnazhagan S, Mahendra G, Kumar S, Thompson J, Castillas Jr M
J Virol . 2002 Nov; 76(24):12900-7. PMID: 12438615
The development of targeted vectors, capable of tissue-specific transduction, remains one of the important aspects of vector modification for gene therapy applications. Recombinant adeno-associated virus type 2 (rAAV-2)-based vectors are...